Laura C.A. Galbraith

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells

Franziska Baenke, Barbara Chaneton, Matthew Smith et al. · Molecular Oncology · 2015 · 191 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>Sleeping Beauty</i> screen reveals <i>Pparg</i> activation in metastatic prostate cancer

Imran Ahmad, Ernest Mui, Laura C.A. Galbraith et al. · Proceedings of the National Academy of Sciences · 2016 · 120 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Bright insights into palladium-triggered local chemotherapy

Thomas L. Bray, Mark J. Salji, Alessandro Brombin et al. · Chemical Science · 2018 · 102 citations · Full text

Medicine, Oncology, Pharmacology +13

Defining functional classes of Barth syndrome mutation in humans

Ya‐Wen Lu, Laura C.A. Galbraith, Jenny D. Herndon et al. · Human Molecular Genetics · 2016 · 73 citations · Full text

Life Sciences, Genetics, Molecular Biology +14